Country: Կանադա
language: անգլերեն
source: Health Canada
DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE)
JUNO PHARMACEUTICALS CORP.
N05CM18
DEXMEDETOMIDINE
400MCG
SOLUTION
DEXMEDETOMIDINE (DEXMEDETOMIDINE HYDROCHLORIDE) 400MCG
INTRAVENOUS
15G/50G
Prescription
MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS
Active ingredient group (AIG) number: 0152679004; AHFS:
APPROVED
2019-04-12
_Dexmedetomidine Hydrochloride Injection _ _Page 1 of 34 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR DEXMEDETOMIDINE HYDROCHLORIDE INJECTION Solution, 4 mcg/mL dexmedetomidine (as dexmedetomidine hydrochloride), intravenous infusion (Ready to use, 50 mL and 100 mL vials) Alpha2-adrenergic agonist Juno Pharmaceuticals Corp. 402-2233 Argentia Road Mississauga, ON L5N 2X7 Date of Initial Authorization: April 12, 2019 Date of Revision: October 12, 2023 Submission Control Number: 274740 _Dexmedetomidine Hydrochloride Injection _ _Page 2 of 34 _ RECENT MAJOR LABEL CHANGES 4.1 Dosing Considerations 10/2023 7.0 Warnings and Precautions 10/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ......................................................................................................... 2 TABLE OF CONTENTS ........................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................... 4 1 INDICATIONS ........................................................................................................................... 4 1.1 Pediatrics ................................................................................................................................. 4 1.2 Geriatrics ................................................................................................................................. 4 2 CONTRAINDICATIONS .............................................................................................................. 4 4 DOSAGE AND ADMINISTRATION .............................................................................................. 4 4.1 Dosing Considerations ............................................................................................................. 5 4.2 Recommended Dose and Dosage Adjust read_full_document